Our Pipeline

Product

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Market

EPX-100 Orphan drug and rare pediatric disease designations for Dravet syndrome have been granted from the FDA. Phase 1 study has been completed in the US. Phase 2 study is ongoing in the US. Detailed Information for EPX-100 Phase 2 study is here

Dravet Syndrome

Lennox Gastuat Syndrome

EPX-101, 102, and 103

Dravet Syndrome

EPX-200 Orphan drug designations for Dravet syndrome have been granted from the FDA and EMA.

Dravet Syndrome

Lennox Gastuat Syndrome

EPX-300Orphan drug designation for Dravet syndrome has been granted from the FDA.

Dravet Syndrome

EPX-100 is a first-generation antihistamine safely used to treat itch in the 1950-1960s. EPX-100 is not currently manufactured or available anywhere in the world. EPX-100 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for DS. EPX-100 antiepileptic action is not through a histaminergic mechanism of action, but acts via modulation of serotonin (5HT) signaling pathways.
EPX-200 is an FDA-approved weight gain management drug which acts via modulation of serotonin (5HT) signaling pathways. EPX-200 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for DS. EPX-200 also showed promising clinical results in terms of reductions in seizure frequency and/or severity in a small group of DS patients.

EPX-101, 102, and 103 are EPX-100 analogs, which have been fully confirmed with zebrafish DS disease models.

All of them were a potent suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish DS disease models.

EPX-300 is an FDA-approved antidepressant, anti-anxiety and sleep-inducing insomnia drug which acts via modulation of serotonin (5HT) signaling pathways. EPX-300 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for DS.

To Learn More